Stomach Cancer
This is a multicenter, open‑label, prospective Phase 1/2a study to assess safety and tolerability, establish dosimetry and to identify an optimal imaging dose (radioactivity) and imaging time window of 64Cu‑LNTH‑1363S, and to compare its imaging biodistribution with FAP expression by IHC in patients with sarcomas or GIT cancers.
Evidence level: Korai humán adat. Kis vagy feltáró emberi adat.
Related signals
- Precision medicine in gastric cancer
- Gastric cancer
- DESTINY‑Gastric05 Phase 3 Trial of ENHERTU Initiated in Patients with Previously Untreated HER2 Positive Advanced Gastric Cancer
- Nivolumab/Chemo Yields Long-Term Survival in Advanced Gastric Cancers
- Current Treatment and Recent Progress in Gastric Cancer